{"changeSha256":"281ec562012d8b28035b9f86f549c8714e1923ad5841833b9909b2ab8d3efbef","changedAt":"2026-11-14","changedFields":[{"after":"A copper-binding peptide that FDA lists, except in injected forms, as under evaluation for pharmacy compounding. None of the sources reviewed reports an FDA approval.","before":"A copper-binding peptide named in FDA's list of bulk substances under evaluation for non-injectable compounding.","field":"Profile summary"},{"after":"Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","before":"FDA lists GHK-Cu, except injectable routes, in Category 1 for bulk substances under evaluation. That listing does not establish FDA approval, safety, or effectiveness.","field":"Evidence note"},{"after":"fda-ghk-cu-503a-2026, fda-ghk-cu-identity, fda-bulk-peptide-risks, journal-pmid-17147644, journal-pmid-16847171, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"fda-ghk-cu-503a-2026, fda-ghk-cu-identity","field":"Cited source records"},{"after":"U.S. Food and Drug Administration [sources: fda-ghk-cu-503a-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]","before":"U.S. Food and Drug Administration [sources: fda-ghk-cu-503a-2026]","field":"Named organizations"},{"after":"name: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; aliases: fda-ghk-cu-identity; category: fda-ghk-cu-503a-2026; status: fda-ghk-cu-503a-2026; summary: fda-ghk-cu-503a-2026; evidenceNote: journal-pmid-17147644, journal-pmid-16847171, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; aliases: fda-ghk-cu-identity; category: fda-ghk-cu-503a-2026; status: fda-ghk-cu-503a-2026; summary: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; evidenceNote: fda-ghk-cu-503a-2026","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ghk-cu/versions/3/","version":3},"id":"profile:ghk-cu:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added a plain-language reader guide with cited answers, re-checked FDA’s May 2026 503A nominations list, added FDA’s compounding safety-risk page and two randomized studies from our human evidence review, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include GHK-Cu.","peptideSlugs":["ghk-cu"],"previousChangeEvent":{"path":"/corrections/v1/profiles/ghk-cu/v2.json","sha256":"cb086842d738b83daac6df9f4c6a838c51083dfdea89d792229fea220f86f898"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ghk-cu/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-ghk-cu-503a-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026","url":"https://www.fda.gov/media/94155/download?attachment","verifiedAt":"2026-07-22"},{"id":"fda-bulk-peptide-risks","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Certain bulk drug substances for use in compounding that may present significant safety risks","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-policy-2026","name":"U.S. Department of Health and Human Services","sourceClass":"A","title":"HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications)","url":"https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"ghk-cu","type":"profile"}}
